Hepatitis C virus peptide compositions and methods of use thereof

Patent metadata

Field	Value
Publication number	US-12048742-B2
Application number	US-201916978486-A
Country	US
Kind code	B2
Filing date	Mar 14, 2019
Priority date	Mar 16, 2018
Publication date	Jul 30, 2024
Grant date	Jul 30, 2024

Abstract

The present disclosure provides an immunogenic composition comprising: a) i) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; ii) an HCV E1 polypeptide; or iii) an HCV E2 polypeptide; b) a polypeptide (also referred to herein as a “T-cell epitope polypeptide” or an “HCV T-cell epitope polypeptide”) comprising T-cell epitopes (e.g., CD4+ and CD8+ T-cell epitopes that are conserved among some HCV genotypes and that are presented through one or multiple HLA alleles common within the human population) present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide.

First claim

What is claimed is:

1. An immunogenic composition comprising:
a) a TP35-NS3 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to:
KSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSK as set forth by SEQ ID NO:133, wherein the T-cell epitope polypeptide has a length of from 28 amino acids to 35 amino acids;
b) a TP50C T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to:
GVYLLPRRGPRLGVRATRKTSERSQPRGRRQPIPKARRSEGRSWAQPGYP as set forth by SEQ ID NO:148, wherein the T-cell epitope polypeptide has a length of from 40 amino acids to 50 amino acids;
c) a TP27 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: LEQIKGGRHLIFCHSKKKCDELAAKLT as set forth by SEQ ID NO:188, wherein the TP27 T-cell epitope polypeptide has a length of from 22 amino acids to 27 amino acids; and
d) a TP48 T-cell epitope polypeptide comprising an amino acid sequence having at least 80% amino acid sequence identity to: ILRRHVGPGEGAVQWMNRLIAFASRGNHVSPTHYVPESDAAARVTQIL as set forth by SEQ ID NO:268, wherein the T-cell epitope polypeptide has a length of from 45 amino acids to 48 amino acids.

2. The immunogenic composition of claim 1 , comprising:
a) a TP35-NS3 T-cell epitope polypeptide comprising an amino acid sequence having at least 95% amino acid sequence identity to:
KSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSK as set forth by SEQ ID NO:133, wherein the T-cell epitope polypeptide has a length of from 28 amino acids to 35 amino acids;
b) a TP50C T-cell epitope polypeptide comprising an amino acid sequence having at least 95% amino acid sequence identity to:
GVYLLPRRGPRLGVRATRKTSERSQPRGRRQPIPKARRSEGRSWAQPGYP as set forth by SEQ ID NO:148, wherein the T-cell epitope polypeptide has a length of from 40 amino acids to 50 amino acids;
c) a TP27 T-cell epitope polypeptide comprising an amino acid sequence having at least 95% amino acid sequence identity to: LEQIKGGRHLIFCHSKKKCDELAAKLT as set forth by SEQ ID NO:188, wherein the TP27 T-cell epitope polypeptide has a length of from 22 amino acids to 27 amino acids; and
d) a TP48 T-cell epitope polypeptide comprising an amino acid sequence having at least 95% amino acid sequence identity to: ILRRHVGPGEGAVQWMNRLIAFASRGNHVSPTHYVPESDAAARVTQIL as set forth by SEQ ID NO:268, wherein the T-cell epitope polypeptide has a length of from 45 amino acids to 48 amino acids.

3. The immunogenic composition of claim 1 , comprising:
a) a TP35-NS3 T-cell epitope polypeptide comprising an amino acid sequence having at least 95% amino acid sequence identity to:
KSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSK as set forth by SEQ ID NO:133, wherein the T-cell epitope polypeptide has a length of 35 amino acids;
b) a TP50C T-cell epitope polypeptide comprising an amino acid sequence having at least 95% amino acid sequence identity to:
GVYLLPRRGPRLGVRATRKTSERSQPRGRRQPIPKARRSEGRSWAQPGYP as set forth by SEQ ID NO:148, wherein the T-cell epitope polypeptide has a length of 50 amino acids;
c) a TP27 T-cell epitope polypeptide comprising an amino acid sequence having at least 95% amino acid sequence identity to: LEQIKGGRHLIFCHSKKKCDELAAKLT as set forth by SEQ ID NO:188, wherein the TP27 T-cell epitope polypeptide has a length of 27 amino acids; and
d) a TP48 T-cell epitope polypeptide comprising an amino acid sequence having at least 95% amino acid sequence identity to: ILRRHVGPGEGAVQWMNRLIAFASRGNHVSPTHYVPESDAAARVTQIL as set forth by SEQ ID NO:268, wherein the T-cell epitope polypeptide has a length of 48 amino acids.

4. The immunogenic composition of claim 1 , comprising:
a) a TP35-NS3 T-cell epitope polypeptide comprising the amino acid sequence:
KSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSK as set forth by SEQ ID NO:133, wherein the T-cell epitope polypeptide has a length of 35 amino acids;
b) a TP50C T-cell epitope polypeptide comprising the amino acid sequence:
GVYLLPRRGPRLGVRATRKTSERSQPRGRRQPIPKARRSEGRSWAQPGYP as set forth by SEQ ID NO:148, wherein the T-cell epitope polypeptide has a length of 50 amino acids;
c) a TP27 T-cell epitope polypeptide comprising the amino acid sequence: LEQIKGGRHLIFCHSKKKCDELAAKLT as set forth by SEQ ID NO:188, wherein the TP27 T-cell epitope polypeptide has a length of 27 amino acids; and
d) a TP48 T-cell epitope polypeptide comprising the amino acid sequence: ILRRHVGPGEGAVQWMNRLIAFASRGNHVSPTHYVPESDAAARVTQIL as set forth by SEQ ID NO:268, wherein the T-cell epitope polypeptide has a length of 48 amino acids.

5. The immunogenic composition of claim 1 , comprising:
a) a TP35-NS3 T-cell epitope polypeptide comprising the amino acid sequence:
KSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSK as set forth by SEQ ID NO:133, wherein the T-cell epitope polypeptide has a length of 35 amino acids;
b) a TP50C T-cell epitope polypeptide comprising the amino acid sequence:
GVYLLPRRGPRLGVRATRKTSERSQPRGRRQPIPKARRSEGRSWAQPGYP as set forth by SEQ ID NO:148, wherein the T-cell epitope polypeptide has a length of 50 amino acids;
c) a TP27 T-cell epitope polypeptide comprising the amino acid sequence: LEQIKGGRHLIFCHSKKKCDELAAKLR as set forth by SEO ID NO:188, wherein the TP27 T-cell epitope polypeptide has a length of 27 amino acids; and
d) a TP48 T-cell epitope polypeptide comprising the amino acid sequence: ILRRHVGPGEGAVQWMNRLIAFASRGNHVSPTHYVPESDAAARVTQIL as set forth by SEQ ID NO:268, wherein the T-cell epitope polypeptide has a length of 48 amino acids.

6. The composition of claim 1 , further comprising a hepatitis C virus (HCV) E1 polypeptide and/or an HCV E2 polypeptide.

7. The composition of claim 6 , wherein the composition comprises an HCV E1 polypeptide and an HCV E2 polypeptide.

8. The composition of claim 7 , wherein the HCV E1 polypeptide and the HCV E2 polypeptide are of the same genotype.

9. The composition of claim 7 , wherein the HCV E1 polypeptide and the HCV E2 polypeptide are of different genotypes.

10. The composition of claim 1 , wherein the adjuvant comprises MF59.

11. The composition of claim 1 , wherein the adjuvant comprises alum.

12. The composition of claim 1 , wherein the adjuvant comprises a glucopyranosyl lipid.

13. A container comprising the immunogenic composition of claim 1 .

14. The container of claim 13 , wherein the container and the composition are sterile.

15. The container of claim 13 , wherein the container is a syringe.

16. A method of inducing an immune response in an individual to a hepatitis C virus (HCV) polypeptide, the method comprising administering to the individual an effective amount of the immunogenic composition of claim 1 .

17. A method of inducing an immune response in an individual to a hepatitis C virus (HCV) polypeptide, the method comprising administering to the individual an effective amount of the immunogenic composition of claim 6 .

18. A method of inducing an immune response in an individual to a hepatitis C virus (HCV) polypeptide, the method comprising administering to the individual an effective amount of the immunogenic composition of claim 7 .

Assignees

• Univ Alberta

Inventors

• Houghton Michael
• Landi Abdolamir
• Logan Michael
• Law John L
• Chen Chao
• Hockman Darren

Classifications

• C12N2770/24234

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2770/24222

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• A61K2039/55505

  Inorganic adjuvants · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P37/04 Primary

  Immunostimulants · CPC title